Primary Outcomes:

Primary Outcome 1 - Measure: Number of participants with dose limiting toxicities (DLTs)

Primary Outcome 1 - Time Frame: Baseline through day 28

Primary Outcome 2 - Measure: Number of participants with treatment emergent adverse events (AEs)

Primary Outcome 2 - Time Frame: Baseline through up to 2 years or until disease progression

Primary Outcome 3 - Measure: Number of participants with laboratory abnormalities

Primary Outcome 3 - Time Frame: Baseline through up to 2 years or until disease progression

Primary Outcome 4 - Measure: Objective Response Rate

Primary Outcome 4 - Time Frame: Baseline through up to 2 years or until disease progression

Condition:

• Advanced Solid Tumors
• Metastatic Solid Tumors

Eligibility

Criteria:
Inclusion Criteria:

- Histologically or cytologically confirmed locally advanced or metastatic NSCLC,
urothelial carcinoma or HNSCC

- Progressed after at least 1 line of treatment and no more than 3 lines of treatment

- At least one measurable lesion as defined by RECIST version 1.1

- ECOG Performance Status 0 or 1

- Adequate Bone Marrow Function

- Adequate Renal Function

- Adequate Liver Function

- Resolved acute effects of any prior therapy

Exclusion Criteria:

- Known active uncontrolled or symptomatic CNS metastases.

- Major surgery, radiation therapy, systemic anti-cancer therapy or investigational
drug(s) within 4 weeks prior to study entry.

- Active, uncontrolled infection, including COVID-19

- Known or suspected hypersensitivity to PF-06939999

- Inability to consume or absorb study drug
Show More

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No